JP2024541900A5 - - Google Patents
Info
- Publication number
- JP2024541900A5 JP2024541900A5 JP2024524402A JP2024524402A JP2024541900A5 JP 2024541900 A5 JP2024541900 A5 JP 2024541900A5 JP 2024524402 A JP2024524402 A JP 2024524402A JP 2024524402 A JP2024524402 A JP 2024524402A JP 2024541900 A5 JP2024541900 A5 JP 2024541900A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- composition
- composition according
- endoxifen
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163272869P | 2021-10-28 | 2021-10-28 | |
| US63/272,869 | 2021-10-28 | ||
| PCT/US2022/048061 WO2023076496A1 (en) | 2021-10-28 | 2022-10-27 | Endoxifen for treatment of cancers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024541900A JP2024541900A (ja) | 2024-11-13 |
| JP2024541900A5 true JP2024541900A5 (enExample) | 2025-11-17 |
Family
ID=86158538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024524402A Pending JP2024541900A (ja) | 2021-10-28 | 2022-10-27 | がんの治療のためのエンドキシフェン |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250041245A1 (enExample) |
| EP (1) | EP4422608A4 (enExample) |
| JP (1) | JP2024541900A (enExample) |
| KR (1) | KR20240093500A (enExample) |
| CN (1) | CN118159259A (enExample) |
| AU (1) | AU2022378576A1 (enExample) |
| CA (1) | CA3232972A1 (enExample) |
| IL (1) | IL312037A (enExample) |
| MX (1) | MX2024005220A (enExample) |
| WO (1) | WO2023076496A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022232924A1 (en) * | 2021-03-11 | 2023-07-06 | Atossa Therapeutics, Inc. | Endoxifen for treatment of ovarian cancer |
| CN117338780A (zh) * | 2023-09-21 | 2024-01-05 | 中国人民解放军海军军医大学 | 帕罗西汀在制备抗肿瘤药物中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013033430A1 (en) * | 2011-09-02 | 2013-03-07 | Wake Forest School Of Medicine | Targeted delivery and prodrug designs for platinum-acridine anti-cancer compounds and methods thereof |
| EP2773340B1 (en) * | 2011-11-04 | 2020-01-08 | Myron R. Szewczuk | Use of neu1 sialidase inhibitors in the treatment of cancer |
| DE102015222031A1 (de) * | 2015-11-10 | 2017-05-11 | Robert Bosch Gesellschaft Für Medizinische Forschung Mbh | Synthese von (Z)-Endoxifenhydrochlorid |
| WO2017127442A1 (en) * | 2016-01-18 | 2017-07-27 | The Regents Of The University Of California | Methods for treating cancer with rorgamma inhibitors |
| JP7662204B2 (ja) * | 2019-07-03 | 2025-04-15 | アトッサ・セラピューティクス・インコーポレイテッド | エンドキシフェンの徐放性組成物 |
| CN115087466A (zh) * | 2019-12-12 | 2022-09-20 | 森迪生物科学公司 | 用于细胞的调控装甲的方法和组合物 |
| AU2022232924A1 (en) * | 2021-03-11 | 2023-07-06 | Atossa Therapeutics, Inc. | Endoxifen for treatment of ovarian cancer |
| CN119300811A (zh) * | 2022-04-26 | 2025-01-10 | 阿托萨治疗学公司 | 高剂量因多昔芬制剂和使用方法 |
-
2022
- 2022-10-27 WO PCT/US2022/048061 patent/WO2023076496A1/en not_active Ceased
- 2022-10-27 AU AU2022378576A patent/AU2022378576A1/en active Pending
- 2022-10-27 CN CN202280071316.2A patent/CN118159259A/zh active Pending
- 2022-10-27 CA CA3232972A patent/CA3232972A1/en active Pending
- 2022-10-27 MX MX2024005220A patent/MX2024005220A/es unknown
- 2022-10-27 JP JP2024524402A patent/JP2024541900A/ja active Pending
- 2022-10-27 US US18/704,892 patent/US20250041245A1/en active Pending
- 2022-10-27 EP EP22888189.2A patent/EP4422608A4/en active Pending
- 2022-10-27 IL IL312037A patent/IL312037A/en unknown
- 2022-10-27 KR KR1020247013409A patent/KR20240093500A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017031160A5 (enExample) | ||
| JP2021120406A5 (ja) | 癌を治療するための組み合わせ物 | |
| JP2022121594A5 (enExample) | ||
| JP2012509889A5 (enExample) | ||
| JP2022537551A5 (enExample) | ||
| Kuriakose et al. | Potential therapeutic strategies for hypertension‐exacerbated cardiotoxicity of anticancer drugs | |
| CN108135901A (zh) | 胆管癌的治疗 | |
| JP2019509253A5 (enExample) | ||
| JP2023088996A5 (enExample) | ||
| JP2010043115A (ja) | 腫瘍転移および癌の治療における５−フルオロウラシルの有効性の増強 | |
| JP2016522202A (ja) | メトホルミン及びジヒドロケルセチンを含む組み合わせ医薬、及びがんの治療のための使用 | |
| JP2023553533A5 (enExample) | ||
| Abdel-Latif et al. | Vitamin C enhances chemosensitization of esophageal cancer cells in vitro | |
| JP2024016209A5 (enExample) | ||
| Toste | Cardio-oncology: Understanding the different mechanisms of cardiovascular toxicity | |
| Frimpong et al. | Development of novel pyrimidine nucleoside analogs as potential anticancer agents: Synthesis, characterization, and In-vitro evaluation against pancreatic cancer | |
| JP2023527794A5 (enExample) | ||
| JP2024125140A5 (enExample) | ||
| Gomez Rodriguez et al. | Synergic effect of anticancer peptide CIGB-552 and Cisplatin in lung cancer models | |
| JP2024527974A5 (enExample) | ||
| JP2024538719A5 (enExample) | ||
| WO2022167158A1 (en) | Dosage regimen for combinations of paclitaxel and balixafortide | |
| JP2024519449A5 (enExample) | ||
| JP2023517671A5 (enExample) | ||
| JP2024511836A5 (enExample) |